Thymosin Alpha-1 (Thymalfasin/Zadaxin): What the Research Shows

The approved immune modulator with decades of clinical data — now caught in the US compounding pharmacy access crisis

Thymosin Alpha-1 occupies an unusual position in the peptide research landscape: it is simultaneously one of the most clinically studied compounds covered on this site and one of the most misunderstood. It is a prescription-approved medication in more than 35 countries, with a clinical trial record spanning five decades, yet it remains unlicensed in the United States and is frequently discussed in self-experimentation communities alongside compounds that have never progressed beyond rodent models. Understanding what that record actually shows—and what it does not—requires more care than most summaries provide.

This article covers the full evidence base for Thymosin Alpha-1: its origins in basic immunology research, its mechanism at the receptor level, the clinical trial record across hepatitis, sepsis, cancer, and vaccine enhancement, the largest randomized controlled trial ever conducted on the compound (and what its primary endpoint failure means), its regulatory status in the United States and globally, and how its real pharmacological profile compares to the claims that circulate in popular discussion. The goal, as always, is to give readers the tools to evaluate the science themselves.

Quick Facts

Peptide Name	Thymosin Alpha-1 (Tα1; thymalfasin)
Type	Synthetic peptide identical to naturally occurring thymic peptide
Amino Acid Length	28 amino acids
Molecular Weight	~3,108 g/mol
Trade Name	Zadaxin (SciClone Pharmaceuticals)
Primary Research Areas	Immune modulation, hepatitis B and C, cancer immunotherapy adjunct, sepsis, vaccine enhancement, COVID-19
Standard Clinical Dose	1.6 mg subcutaneous injection, twice weekly
Regulatory Status	Approved in 35+ countries; not FDA-approved in the United States; FDA orphan drug designation (hepatitis B, malignant melanoma, DiGeorge syndrome, hepatocellular carcinoma); FDA Category 2 bulk drug substance (2023)
WADA Status	Not prohibited
Evidence Tier	APPROVED DRUG  Zadaxin approved in 35+ countries; not FDA-approved in US

---

What Is Thymosin Alpha-1?

Thymosin Alpha-1 is a 28-amino-acid peptide that occurs naturally in the human body, produced primarily by thymic epithelial cells. It belongs to a family of small proteins collectively called thymosins, originally isolated from thymus tissue in the 1960s and 1970s during the foundational period of clinical immunology. The thymus gland—responsible for T-lymphocyte maturation—produces Tα1 as part of its broader role in establishing and maintaining immune competence, particularly early in life.

As a research compound, Thymosin Alpha-1 is administered as a synthetic peptide that is chemically identical to the endogenous protein. Endogenous Tα1 levels are measurable in human serum but decline with age, paralleling the known involution of the thymus gland. This age-related decline is one of the biological rationales offered for its use in aging, immunodeficiency, and chronic infection contexts, though demonstrating that exogenous supplementation corrects clinically meaningful immune deficits in otherwise healthy adults remains an active area of investigation.

The commercial form, Zadaxin (thymalfasin), is manufactured by SciClone Pharmaceuticals and is approved for clinical use in more than 35 countries across Asia, Europe, Latin America, and the Middle East. In those jurisdictions, it functions as a prescription medication—not a research compound—primarily for hepatitis B, hepatitis C (in combination with interferon), and as an adjunct in certain cancer immunotherapy protocols. In the United States, it is not approved by the FDA for any indication, though it holds orphan drug designations for four conditions and was, until recently, accessible through compounding pharmacies before its 2023 reclassification.

---

Origins and Discovery

The story of Thymosin Alpha-1 begins with a broader scientific project: understanding what the thymus actually does. For much of the mid-twentieth century, the thymus was considered a vestigial organ with no clear function. That changed in the early 1960s when immunologist Jacques Miller demonstrated in mice that neonatal thymectomy produced profound immunodeficiency—a finding that established the thymus as essential to T-cell development and opened an entire field of thymic biology.

Allan Goldstein and his colleagues at the Albert Einstein College of Medicine took this discovery in a pharmacological direction. Beginning in the late 1960s, Goldstein’s laboratory began extracting and characterizing a complex mixture of proteins from calf thymus tissue, which they called Thymosin Fraction 5. This crude extract was shown to restore immune function in thymectomized animals and to stimulate lymphocyte differentiation in vitro. Early clinical trials with Thymosin Fraction 5 showed some promise in immunodeficiency diseases, establishing the therapeutic potential of thymic peptides, but the mixture was pharmacologically complex and difficult to characterize.

The isolation of Thymosin Alpha-1 as a distinct, definable molecule came in 1977, when Goldstein’s group purified it from Thymosin Fraction 5 and characterized its primary structure: a 28-amino-acid peptide with an N-terminal acetyl group. This acetylation—the addition of an acetyl group to the amino terminus—was a key finding because it confers metabolic stability and contributes to the peptide’s biological activity. Synthetic production of the identical peptide became possible shortly thereafter, removing dependence on biological extraction and enabling reproducible clinical research.

Early clinical studies in the 1980s and 1990s focused on immunodeficiency states, DiGeorge syndrome (a congenital condition characterized by thymic hypoplasia and T-cell deficiency), and chronic viral hepatitis—the last of which became the primary commercial indication. SciClone Pharmaceuticals licensed the compound and developed Zadaxin, receiving approvals in multiple Asian markets, where hepatitis B prevalence made the compound commercially viable before large-scale Western regulatory approval was sought.

---

Thymosin Alpha-1 vs. Thymosin Beta-4: Clearing Up the Naming Confusion

One of the most persistent sources of confusion in popular discussion of thymic peptides involves the relationship between Thymosin Alpha-1 and Thymosin Beta-4—the latter being the parent compound of TB-500, one of the most widely discussed tissue repair peptides in self-experimentation communities. The shared word “thymosin” creates an impression of close biological relationship that does not exist at the mechanistic level.

Both peptides were originally isolated from thymus tissue as part of the Thymosin Fraction 5 extraction project, which is why they share the thymosin nomenclature. But they are structurally and functionally distinct molecules:

Thymosin Alpha-1 is 28 amino acids with an N-terminal acetyl group. Its primary biological activity is immunomodulatory—it acts on T-cell maturation, innate immune signaling, and cytokine regulation. It has essentially no effect on actin dynamics or tissue repair.

Thymosin Beta-4 is 43 amino acids. Its primary biological activity is cytoskeletal—it sequesters G-actin monomers, regulating actin polymerization, and promotes cell migration and tissue repair. TB-500 is a 7-amino-acid fragment of Thymosin Beta-4 (the LKKTETQ sequence), believed to retain some of the parent molecule’s biological activity.

These are not two forms of the same compound. They share an historical origin in thymus tissue research and a shared nomenclature convention, but they have different amino acid sequences, different receptors and binding partners, different biological functions, and different clinical applications. A reader researching one will find the other frequently mentioned in the same breath, but they should be understood as pharmacologically independent entities. Any source that treats “thymosin” as a single compound category is presenting an oversimplification that obscures rather than clarifies the science.

---

Mechanism of Action

Thymosin Alpha-1’s immunomodulatory effects operate through several intersecting pathways. The compound does not act through a single receptor in the way that, for example, GLP-1 receptor agonists act through a single well-characterized receptor class. Instead, Tα1 engages the innate immune system through pattern recognition pathways and influences the adaptive immune system through downstream cytokine signaling. This complexity is both scientifically interesting and a source of ongoing mechanistic debate.

Toll-Like Receptor Signaling

The most rigorously characterized mechanism of Tα1 involves toll-like receptors (TLRs)—pattern recognition receptors that function as the immune system’s first line of threat detection. Specifically, Tα1 has been shown to signal through TLR2 and TLR9 on dendritic cells and monocytes. TLR2 recognizes bacterial lipoproteins and peptidoglycans; TLR9 recognizes unmethylated CpG DNA motifs associated with bacterial and viral pathogens. Tα1’s engagement of these receptors triggers activation of the NF-κB signaling pathway, a master regulator of immune gene expression.

The consequence of NF-κB activation downstream of TLR2/TLR9 signaling is induction of type I interferons (IFN-α, IFN-β) and pro-inflammatory cytokines including interleukin-6 (IL-6), interleukin-12 (IL-12), and tumor necrosis factor-alpha (TNF-α). IL-12 in particular is a key driver of T-helper 1 (Th1) immune polarization—the branch of adaptive immunity associated with antiviral defense and cytotoxic T-cell responses. This mechanistic link between Tα1 and Th1 polarization provides a biological rationale for its use in chronic viral infections, where immune exhaustion and Th2 skewing are common features of disease progression.

T-Cell Maturation and Differentiation

Within the thymus, T-cell precursors (thymocytes) undergo a complex maturation process involving positive and negative selection that results in mature, self-tolerant, antigen-specific T cells. Thymosin Alpha-1 promotes this maturation process, particularly the differentiation of immature thymocytes toward the CD4+ T-helper and CD8+ cytotoxic T-cell lineages. This is consistent with its origin as a thymus-derived peptide and with early clinical observations that it restored immune function in thymectomized animals.

In addition to T-cell maturation, Tα1 has been shown to promote the differentiation of T regulatory cells (Tregs) in certain contexts—a finding with potentially important implications for autoimmune disease. Tregs suppress excessive immune responses and help maintain self-tolerance. The dual ability to promote effector T-cell maturation while also supporting Treg development suggests that Tα1’s immunomodulatory effects are bidirectional and context-dependent rather than simply stimulatory.

Natural Killer Cell Activation

Natural killer (NK) cells are innate immune lymphocytes that provide early defense against virally infected cells and tumor cells without requiring prior antigen sensitization. Thymosin Alpha-1 has been shown to enhance NK cell cytotoxicity in vitro and in clinical trial populations, an effect attributed partly to its induction of cytokines (particularly IFN-γ and IL-2) that serve as NK cell activating signals. This mechanism contributes to the rationale for Tα1 use in cancer immunotherapy contexts, where NK cell activity is often suppressed in tumor microenvironments.

Pharmacokinetics

Thymosin Alpha-1 is administered subcutaneously due to rapid degradation in the gastrointestinal tract—the peptide is not orally bioavailable. Following subcutaneous injection, it is absorbed relatively quickly, reaching peak plasma concentrations within approximately 2 hours. Its half-life is short, estimated at roughly 2 hours in clinical pharmacokinetic studies. Despite this short systemic half-life, the biological effects of Tα1—mediated through receptor activation and downstream gene expression changes—are thought to persist substantially longer than the circulating peptide itself, which is consistent with the twice-weekly dosing schedule used in clinical trials.

---

Key Research Areas and Studies

Chronic Hepatitis B

Hepatitis B remains the primary approved indication for Thymosin Alpha-1 in the countries where Zadaxin is licensed. The rationale is well-grounded: chronic hepatitis B is characterized by immune exhaustion, with HBV-specific T cells showing impaired function and a Th2-skewed cytokine environment that fails to clear the virus. Tα1’s ability to promote Th1 polarization and restore T-cell responsiveness to viral antigens provided a mechanistic basis for clinical investigation.

Clinical trials conducted primarily in Asian populations (where hepatitis B prevalence is highest) demonstrated improved rates of hepatitis B e-antigen (HBeAg) seroconversion and hepatitis B surface antigen (HBsAg) clearance compared to placebo or standard of care in the 1990s and early 2000s. A meta-analysis of randomized controlled trials published in 2010 found that Tα1 monotherapy significantly increased HBeAg clearance rates. However, the landscape for hepatitis B treatment has shifted substantially with the introduction of nucleos(t)ide analogues (entecavir, tenofovir) that achieve near-complete virological suppression with high tolerability. Tα1’s role in modern hepatitis B management is now primarily as an adjunct therapy in patients who fail to respond to first-line antivirals, rather than as a standalone treatment.

Chronic Hepatitis C

Before the development of direct-acting antivirals (DAAs) that now cure hepatitis C in the vast majority of patients, interferon-alpha plus ribavirin was the standard of care. Thymosin Alpha-1 was investigated as an addition to this regimen, with the rationale that its immunostimulatory effects would complement interferon’s antiviral activity. Several trials in the late 1990s and 2000s demonstrated improved sustained virological response (SVR) rates when Tα1 was added to interferon-based regimens, particularly in difficult-to-treat populations including patients with HCV genotype 1 and those who had failed prior interferon therapy.

The arrival of DAA regimens (sofosbuvir-based combinations achieving >95% SVR rates) has rendered this application largely historical in regions with access to modern antivirals. Tα1 is no longer a clinically relevant hepatitis C treatment in developed markets. The research remains scientifically interesting as a demonstration of immune adjuvant effects but has limited practical contemporary significance.

Sepsis

Sepsis represents one of the most important and contested areas of Tα1 research. The biological rationale is compelling: sepsis is characterized by profound immune dysregulation, with initial hyperinflammation often followed by immunosuppression that leaves patients vulnerable to secondary infections. Tα1’s immunomodulatory properties—particularly its ability to restore T-cell function and activate innate immune signaling—suggested potential utility in reversing sepsis-associated immunosuppression.

Multiple smaller randomized controlled trials, particularly from Chinese academic centers, reported significant mortality reductions with Tα1 in septic patients. A meta-analysis published in 2019 pooling these studies suggested a 28-day mortality benefit. These findings generated substantial clinical and commercial interest.

The TESTS trial (Thymosin Alpha-1 for the Treatment of Severe Sepsis) put these findings to a rigorous test. Conducted across 22 centers in China, the TESTS trial enrolled 1,106 patients with severe sepsis in a double-blind, placebo-controlled design—the largest RCT of Tα1 ever conducted for any indication. Results published in 2023 found no statistically significant reduction in the primary endpoint: 28-day all-cause mortality. The trial did identify post-hoc subgroup signals suggesting potential benefit in elderly patients and those with diabetes, but pre-specified primary endpoint failure is the clinically and methodologically decisive finding. The TESTS result does not definitively prove that Tα1 is ineffective in sepsis—it is possible that specific patient subgroups benefit, or that optimal dosing and timing differ from the protocol used—but it substantially raises the evidentiary bar for this application.

Vaccine Enhancement

Several studies have examined Tα1 as an adjuvant to improve vaccine immunogenicity, particularly in populations with diminished immune responsiveness such as the elderly, dialysis patients, and individuals with chronic liver disease. The rationale follows directly from its mechanism: by stimulating T-cell maturation and TLR-mediated innate immune activation, Tα1 may prime the immune system to mount more robust responses to vaccine antigens.

Studies of Tα1 co-administration with influenza vaccines in elderly subjects demonstrated enhanced antibody titers and improved seroprotection rates compared to vaccine alone. Similar enhancement has been reported with hepatitis B vaccines in non-responders—patients who fail to seroconvert with standard vaccination schedules. These findings have real clinical relevance in the context of aging populations with diminishing vaccine responsiveness, though this indication has not been formally licensed in most markets.

COVID-19

During the COVID-19 pandemic, Tα1 attracted renewed interest based on its established immunomodulatory profile. Chinese researchers published observational data and small RCTs suggesting that Tα1 administration in critically ill COVID-19 patients reduced mortality and accelerated clinical improvement, with the proposed mechanism involving restoration of lymphocyte function in patients with severe COVID-associated lymphopenia. These studies received significant attention in both clinical and self-experimentation communities.

Methodological limitations of the COVID-19 Tα1 studies—including small sample sizes, heterogeneous patient populations, rapid publication under pandemic conditions, and limited independent replication outside China—mean that these findings should be interpreted cautiously. They represent a signal warranting further investigation rather than established efficacy. Larger, well-controlled trials in COVID-19 populations have not been completed as of this writing.

Cancer Immunotherapy Adjunct

Tα1 has been investigated as an adjunct to conventional cancer therapy in several tumor types, including non-small cell lung cancer, hepatocellular carcinoma, and malignant melanoma (the last of which is one of its FDA orphan drug indications). The rationale involves restoring immune competence in cancer patients, whose immune systems are often suppressed by both the tumor and the cytotoxic effects of chemotherapy and radiation. Clinical data support improvements in immune parameters (T-cell counts, NK cell activity) and some quality-of-life outcomes, but demonstration of survival benefit has been inconsistent across studies. This remains an active area of investigation, particularly in the context of combination with checkpoint inhibitors.

---

Common Claims versus Current Evidence

Claim	Current Evidence
“Boosts the immune system”	Partially supported but significantly oversimplified. Tα1 modulates immune function bidirectionally—promoting Th1 responses while also supporting T regulatory cell activity. It does not simply amplify immune output. The clinical populations in which benefit has been demonstrated share impaired or dysregulated baseline immune function (chronic viral infection, immune exhaustion, aging). Extrapolation to healthy adults with normally functioning immune systems is not supported by current evidence.
“Treats hepatitis B and C”	Supported by clinical trial evidence and regulatory approval in 35+ countries for hepatitis B. For hepatitis C, evidence supported use with interferon-based regimens, but direct-acting antivirals have made this largely obsolete in regions where DAAs are available. Modern clinical role is primarily as a second-line adjunct in antiviral-refractory hepatitis B cases.
“Reduces mortality in sepsis”	Earlier smaller trials and meta-analyses suggested benefit. The TESTS trial (n=1,106, double-blind RCT) did not meet its primary endpoint of 28-day mortality reduction. Subgroup signals exist but require prospective validation. The claim requires significant qualification at the current state of evidence.
“Enhances vaccine effectiveness”	Supported by controlled trial data in elderly populations and non-responders to hepatitis B vaccination. Mechanistically coherent given Tα1’s documented effects on T-cell maturation and TLR signaling. Not formally licensed as a vaccine adjuvant in most markets.
“Prevents illness and general infections”	Not supported by clinical trial data in healthy populations. No large, well-controlled RCTs have examined prophylactic Tα1 use for infection prevention in immunocompetent adults. This use extrapolates from mechanism and from trial data in immunocompromised or elderly populations without direct evidence.
“Anti-aging and longevity effects”	Speculative. The premise—that declining endogenous Tα1 with age contributes to immunosenescence—is mechanistically plausible. Whether exogenous replacement reverses clinically meaningful markers of immune aging has not been demonstrated in rigorous human trials. This is hypothesis-generation, not established biology.

---

The Human Evidence Landscape

Thymosin Alpha-1 has one of the richest human evidence bases of any compound covered on this site. The total literature spans several hundred published clinical studies, including dozens of randomized controlled trials. This is not a compound extrapolated from cell culture or rodent models—it has been administered to tens of thousands of human patients under controlled research conditions over five decades.

That said, the evidence base has important structural limitations that deserve honest assessment.

Geographic concentration: A substantial proportion of the clinical trial literature—particularly the sepsis, COVID-19, and cancer adjuvant studies—originates from Chinese research centers. While this reflects legitimate clinical use patterns (Zadaxin has long been approved and commercially available in China), it also means that independent replication in different healthcare systems, patient populations, and regulatory contexts is limited. Single-region evidence bases should be interpreted with more caution than multi-national replicated findings.

The TESTS trial and prior probability: The TESTS sepsis trial result is methodologically significant beyond its specific finding. It was conducted after a body of smaller positive trials had built enthusiasm for Tα1 in sepsis—a pattern familiar from other clinical areas where small positive trials predict large trial failure. The TESTS result is a reminder that Tα1’s immunomodulatory effects, however real, do not automatically translate into mortality benefit in the complex pathophysiology of sepsis.

Historical displacement: The hepatitis B and C applications—the most robustly supported clinical uses—have been substantially displaced by newer treatments (nucleos(t)ide analogues for HBV, DAAs for HCV) that are more effective, better tolerated, and available in more markets. Tα1’s strongest clinical evidence applies to therapeutic contexts that are no longer first-line in most of the world.

Approved drug status is real: None of the above qualifications should obscure the fundamental fact that Thymosin Alpha-1 is a real prescription medication with genuine regulatory approval in dozens of countries, based on genuine clinical trial evidence. This distinguishes it categorically from research chemicals with no human evidence, and from compounds whose claimed mechanisms have never been tested in humans.

---

Safety, Risks, and Limitations

Thymosin Alpha-1 has a well-characterized safety profile based on decades of clinical use. Across the clinical trial literature, it has consistently demonstrated a favorable tolerability profile with a low rate of serious adverse events.

Common Adverse Effects

The most frequently reported adverse effects are injection-site reactions—localized redness, mild swelling, and occasional bruising at the subcutaneous injection site. These are generally mild, transient, and self-resolving. Systemic adverse effects reported in clinical trials include transient fatigue, mild flu-like symptoms in a small proportion of patients, and occasional headache. These are generally consistent with an immune-activating effect rather than direct toxicity.

Autoimmune Conditions: A Meaningful Caution

Interaction with Immunosuppressive Therapy

Individuals receiving deliberate immunosuppression—organ transplant recipients, patients on long-term corticosteroids, or those receiving immunosuppressive therapy for autoimmune conditions—should be aware that Tα1’s immune-activating effects could work at direct cross-purposes with their therapeutic regimen. This interaction has not been well-studied in controlled trials, and the clinical implications would depend on the specific immunosuppressive drugs, doses, and clinical context involved.

Pregnancy and Pediatric Populations

Data on Tα1 safety in pregnancy is limited. Animal studies have not shown teratogenicity, but human gestational safety data is insufficient to characterize risk. Pediatric use has been studied in DiGeorge syndrome and congenital immunodeficiency contexts, but these are specialized clinical applications managed by pediatric immunologists. Off-label pediatric use outside these specific contexts is not supported by available safety data.

Long-Term Safety

The long-term safety profile of Tα1 in clinical use contexts is generally considered favorable, with no pattern of serious delayed toxicity emerging from decades of post-marketing experience in countries where Zadaxin is approved. However, most clinical trials are of limited duration (weeks to months), and rigorous long-term follow-up data from randomized trials is not systematically available. The absence of observed problems is reassuring but is not equivalent to a confirmed absence of risk with long-term repeated use.

---

Legal and Regulatory Status

Global Approved Status

Thymosin Alpha-1 (Zadaxin, thymalfasin) is an approved prescription medication in more than 35 countries, including China, Italy, Singapore, the Philippines, Peru, and numerous other Asian, European, and Latin American markets. In these jurisdictions, it is a licensed pharmaceutical product manufactured under pharmaceutical-grade standards and dispensed through normal prescription channels. The approved indications vary by country but primarily include chronic hepatitis B, chronic hepatitis C (typically in combination with interferon), and use as an immune modulator in cancer contexts.

United States: FDA Status

Thymosin Alpha-1 is not approved by the U.S. Food and Drug Administration for any therapeutic indication. It holds FDA orphan drug designations for four conditions—chronic hepatitis B, malignant melanoma, DiGeorge syndrome, and hepatocellular carcinoma—but orphan drug designation is not the same as approval; it designates a compound as promising for a rare condition and provides certain research and regulatory incentives without conferring marketing authorization.

In 2023, the FDA placed Thymosin Alpha-1 on its Category 2 bulk drug substance list under 503A and 503B compounding regulations. Category 2 designation means that the agency has determined there is insufficient evidence of clinical use and the compound raises concerns—effectively restricting compounding pharmacies in the United States from preparing Tα1 for individual patient prescriptions. This 2023 reclassification substantially changed the compound’s accessibility through domestic US channels that had previously supplied it.

WADA Status

Thymosin Alpha-1 is not prohibited by the World Anti-Doping Agency and does not appear on the WADA Prohibited List. This is a meaningful distinction from several other peptides covered on this site—TB-500 (Thymosin Beta-4), for instance, is prohibited at all times under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Athletes subject to WADA-compliant drug testing can confirm this status annually through WADA’s official prohibited list publication.

Jurisdictional Variation

The regulatory landscape for Tα1 is genuinely complex: it is a licensed prescription drug in dozens of countries and effectively restricted in the United States. Readers in different jurisdictions face different legal frameworks. This variability is itself a form of regulatory information—a compound with legitimate pharmaceutical approval in 35+ countries is not in the same regulatory category as a research chemical with no approval anywhere—but individual legal compliance depends on specific national law. Peptidings does not provide legal advice. Determining what is lawful in any specific jurisdiction is the responsibility of the reader.

---

Research Protocols and Laboratory Practices

This section describes the handling, storage, and administration practices documented in the clinical research literature and applicable to research settings. It is not a guide to self-administration.

Commercial Form and Reconstitution

Zadaxin is supplied as a lyophilized (freeze-dried) powder in single-dose vials containing 1.6 mg of thymalfasin, accompanied by a 1 mL ampoule of sterile water for injection. Reconstitution is performed by adding the sterile water to the lyophilized powder under aseptic technique; the resulting solution is for immediate subcutaneous injection. The commercial product does not require complex reconstitution procedures—it is designed as a pharmacy-dispensed, clinician-administered or patient self-administered therapeutic.

Storage

Lyophilized Tα1 is stable at room temperature for the shelf life specified on the commercial product label. Reconstituted solution should be used immediately and not stored. The product should be protected from light and kept away from temperatures exceeding 25°C (77°F). As with all peptide therapeutics, exposure to extreme temperatures, repeated freeze-thaw cycles, or moisture can degrade activity.

Route of Administration

All clinical research on Thymosin Alpha-1 has used subcutaneous injection as the route of administration. Subcutaneous injection delivers the peptide into the adipose tissue layer beneath the skin, from which it is absorbed into the lymphatic and vascular systems. Intravenous or intramuscular administration are not part of the established clinical protocol for Tα1. Oral administration is not viable—the peptide is degraded in the gastrointestinal tract before reaching systemic circulation at meaningful concentrations.

---

Dosing in Published Research

Study / Source	Population	Dose	Route	Frequency	Duration	Key Findings
Hepatitis B RCTs (multiple; Zadaxin pivotal trials)	Chronic HBV patients	1.6 mg	SC	Twice weekly	6–12 months	Improved HBeAg seroconversion and HBsAg clearance vs. placebo; basis for international approvals
Hepatitis C + interferon trials (multiple)	Chronic HCV, including genotype 1 non-responders	1.6 mg	SC	Twice weekly	6–12 months	Improved SVR rates vs. interferon alone; largely superseded by DAA regimens
TESTS Trial (Wu et al., 2023)	Severe sepsis, n=1,106, 22 Chinese centers	1.6 mg	SC	Twice daily × 5 days	5 days	Primary endpoint (28-day mortality) not met; subgroup signals in elderly and diabetic patients observed
Influenza vaccine enhancement (Crary et al. and related)	Elderly subjects (≥65 years)	900 mcg–1.6 mg	SC	Prior to and post-vaccination	2–4 weeks perivacc.	Improved antibody titers and seroprotection rates vs. vaccine alone in elderly populations
HBV vaccine non-responders (multiple)	Dialysis patients and immunocompromised non-responders to HBV vaccine	1.6 mg	SC	Twice weekly perivacc.	4–8 weeks	Improved seroconversion in HBV vaccine non-responders; mechanistically consistent with TLR adjuvant effect

---

Dosing in Independent Self-Experimentation Communities

Protocol Parameter	Typical Community Range	Notes
Dose per injection	0.5 mg – 1.6 mg	1.6 mg is the standard Zadaxin clinical dose; community users often begin at lower doses (0.5–0.9 mg)
Frequency	1–2 times per week	Twice-weekly mirrors the clinical protocol; some use once-weekly for maintenance or cost reasons
Cycle duration	4–12 weeks	Clinical trials used longer courses (6–12 months) for hepatitis; shorter self-experimentation cycles reflect general immune optimization goals rather than chronic infection treatment
Route	Subcutaneous	Consistent with clinical protocol; no established basis for alternative routes
Primary reported uses	General immune optimization, illness prevention, adjunct during immune stressors (travel, illness exposure)	None of these applications have been validated in controlled trials in immunocompetent healthy adults
Monitoring in community use	Rarely systematic	Clinical trials monitored immune cell counts, cytokine panels, and liver function. Self-experimentation typically does not include this monitoring. Given Tα1 acts on the immune system, absence of baseline immune profiling is a more significant gap than for tissue-repair peptides, where effects are externally observable

---

Frequently Asked Questions

Is Thymosin Alpha-1 the same as Thymosin Beta-4 or TB-500?

No. Despite sharing the word “thymosin,” these are distinct molecules with different amino acid sequences, different mechanisms of action, and different clinical applications. Thymosin Alpha-1 (28 amino acids) is an immune modulator acting through TLR2/TLR9 and T-cell maturation pathways. Thymosin Beta-4 (43 amino acids) and its research fragment TB-500 act on actin cytoskeletal dynamics and are studied primarily for tissue repair. Both were historically isolated from thymus tissue, which explains the shared nomenclature, but they are pharmacologically independent compounds.

Is Thymosin Alpha-1 FDA approved?

No. Thymosin Alpha-1 (Zadaxin/thymalfasin) is not FDA-approved for any therapeutic indication in the United States. It holds FDA orphan drug designations for chronic hepatitis B, malignant melanoma, DiGeorge syndrome, and hepatocellular carcinoma—but orphan drug designation is not approval. In 2023, the FDA placed it on the Category 2 bulk drug substance list, restricting compounding pharmacy access. It is, however, an approved prescription medication in more than 35 other countries.

Is Thymosin Alpha-1 prohibited in sport?

No. Thymosin Alpha-1 is not on the WADA Prohibited List and is not prohibited in competitive sport. This stands in contrast to TB-500 (prohibited at all times, S2), BPC-157 (prohibited under S0), and several growth hormone-related compounds covered elsewhere on this site. Athletes subject to WADA-compliant anti-doping rules should always verify current status against the annual WADA Prohibited List publication, as the list is updated each year.

What happened in the TESTS sepsis trial?

The TESTS trial was the largest randomized controlled trial of Thymosin Alpha-1 ever conducted for any indication: 1,106 patients with severe sepsis enrolled across 22 Chinese centers in a double-blind, placebo-controlled design. The primary endpoint—28-day all-cause mortality—was not met. The trial did identify subgroup signals suggesting potential benefit in elderly and diabetic patients, but these are hypothesis-generating findings requiring prospective validation, not established efficacy claims. The TESTS result does not mean Tα1 is definitively ineffective in sepsis, but it substantially changes the evidentiary picture relative to earlier smaller positive trials.

Can Thymosin Alpha-1 worsen autoimmune conditions?

This is a genuine concern. By promoting T-cell activity and Th1 immune polarization, Tα1 could theoretically exacerbate autoimmune processes. Clinical trials have generally excluded patients with active autoimmune disease, so the safety profile in these populations is not well-characterized. Individuals with autoimmune conditions—rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease, and others—should not use Tα1 without explicit discussion with their treating physician.

Does Thymosin Alpha-1 decline with age and can supplementation reverse this?

Endogenous Tα1 levels do decline with age, paralleling thymic involution. This decline is one biological rationale for interest in exogenous Tα1 in aging and longevity contexts. However, whether supplementing exogenous Tα1 meaningfully reverses age-related immune decline in healthy adults—and whether any such reversal translates into clinical benefit—has not been demonstrated in rigorous human trials. The premise is mechanistically plausible but the application to healthy aging remains speculative.

Why is Thymosin Alpha-1 approved in 35+ countries but not the United States?

The primary reason is commercial and regulatory history rather than a scientific determination that the compound is unsafe or ineffective. Zadaxin was developed and licensed primarily in Asian markets where hepatitis B prevalence made commercial viability straightforward. SciClone Pharmaceuticals obtained approvals in those markets and in several European and Latin American countries. Seeking FDA approval requires specific, large-scale US-conducted clinical trials meeting FDA-specific endpoints and protocols—a costly undertaking that was not commercially prioritized for the US market given the competitive landscape (hepatitis B antivirals, in particular) and the regulatory complexity. The FDA’s 2023 Category 2 designation further reflects the FDA’s assessment that existing evidence does not meet its standards for compounding use, which is a separate question from the compound’s approved status elsewhere.

---

Related Peptides: How Thymosin Alpha-1 Compares

Within the Tissue Repair and Immune Modulation cluster, Thymosin Alpha-1 occupies a distinct position. It is the only compound in Cluster B with approved-drug status in major international markets, and it is the only one whose primary mechanism is immunological rather than structural or regenerative.

Feature	Thymosin Alpha-1	BPC-157	TB-500	GHK-Cu	KPV
Primary mechanism	TLR2/TLR9 signaling; T-cell maturation; cytokine modulation	Angiogenesis; NO signaling; cytoprotection	Actin sequestration (via Tβ4 parent); cell migration	Copper-dependent matrix remodeling; anti-inflammatory	MC1R agonism; NF-κB modulation; anti-inflammatory
Evidence tier	APPROVED DRUG	PRECLINICAL	PRECLINICAL	PILOT	PRECLINICAL
Human trials	Extensive—dozens of RCTs including n=1,106 TESTS trial	No published human RCTs as of writing	No published human trials (Tβ4 parent: some topical cosmetic trials)	Multiple topical cosmetic trials; no systemic human data	Very limited; smallest evidence base in cluster
WADA status	Not prohibited	Prohibited (S0)	Prohibited at all times (S2)	Not prohibited	Not prohibited
FDA status	Orphan drug designation (4 indications); Category 2—compounding restricted; not approved	Category 1 (non-injectable); injectable restricted; no approval	Not approved; research chemical; Tβ4 parent in FDA pipeline	GRAS status (oral/topical); injectable restricted; no approval	Not approved; research chemical
Unique safety concern	Immune modulation unpredictable in autoimmune conditions; potential interaction with immunosuppressive therapy	Research concentrated in single group; limited independent replication	Tβ4 parent overexpressed in some tumor types; theoretical promotion risk	Copper accumulation with chronic systemic use; short half-life limits bioavailability	Very limited safety data; smallest evidence base in cluster

What the comparison reveals: Thymosin Alpha-1 is categorically different from the other compounds in this cluster from an evidentiary standpoint. Its approved-drug status in 35+ countries, its extensive RCT record, and its well-characterized mechanism distinguish it from BPC-157, TB-500, and KPV, which remain preclinical-only compounds with no human trial data. GHK-Cu occupies an intermediate position with human cosmetic trial data. The comparison also highlights that the self-experimentation community’s interest in all five compounds tends to conflate very different evidence tiers under the broad umbrella of “peptides”—a framing that serves no reader who wants to actually understand what the science supports.

---

Summary and Key Takeaways

• Thymosin Alpha-1 is a 28-amino-acid endogenous peptide originally isolated from thymus tissue and now produced synthetically as Zadaxin (thymalfasin).
• It is an approved prescription medication in more than 35 countries—primarily for chronic hepatitis B and C—and holds FDA orphan drug designation for four indications in the United States, where it is not approved and where compounding access was restricted in 2023.
• Its mechanism operates primarily through TLR2/TLR9 innate immune signaling, T-cell maturation, NK cell activation, and cytokine modulation—a profile that is immunomodulatory rather than simply immunostimulatory.
• The clinical evidence base is the largest of any compound in its cluster, spanning several hundred published studies and multiple RCTs. However, the largest and most rigorous trial (TESTS, n=1,106 in sepsis) failed its primary endpoint, introducing meaningful uncertainty about the sepsis application that had attracted the most recent clinical interest.
• It is not prohibited by WADA—a meaningful distinction from TB-500 and BPC-157.
• Its strongest supported applications (chronic hepatitis B adjunct, vaccine enhancement in immunocompromised populations) involve disease states or immune impairment. Its use in healthy adults for general immune optimization lacks clinical trial validation.
• Thymosin Alpha-1 and Thymosin Beta-4/TB-500 are not the same compound and should not be treated as related pharmacological entities despite sharing nomenclature.
• Autoimmune conditions and concurrent immunosuppressive therapy represent meaningful safety considerations that should not be minimized in community discussions.

---

Selected References and Key Studies

• Goldstein AL, Guha A, Zatz MM, Hardy MA, White A. “Purification and biological activity of thymosin, a hormone of the thymus gland.” Proceedings of the National Academy of Sciences. 1972;69(7):1800–1803.
• Goldstein AL, Low TL, McAdoo M, et al. “Thymosin alpha 1: isolation and sequence analysis of an immunologically active thymic polypeptide.” Proceedings of the National Academy of Sciences. 1977;74(2):725–729.
• Romani L, Bistoni F, Gaziano R, et al. “Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling.” Blood. 2004;103(11):4232–4239.
• Ancell CD, Phipps J, Young L. “Thymosin alpha-1.” American Journal of Health-System Pharmacy. 2001;58(10):879–885.
• Wu J, Zhou L, Liu J, et al. “The efficacy of thymosin alpha 1 for severe sepsis (TESTS): a multicenter, randomized, double-blind, placebo-controlled trial.” Critical Care. 2023.
• Liu J, Wu J, Dong M, et al. “Thymosin alpha-1 treatment in severe sepsis: a systematic review and meta-analysis.” Journal of Critical Care. 2019.
• Pica F, Gaziano R, Casalinuovo IA, et al. “Serum thymosin alpha 1 levels in normal and pathological conditions.” Expert Opinion on Biological Therapy. 2018;18(sup1):13–21.
• Garaci E, Pica F, Rasi G, Mastino A. “Thymosin alpha-1 in the treatment of cancer: from basic research to clinical application.” International Journal of Immunopharmacology. 2000;22(12):1067–1076.

---

Further Reading and References

• ClinicalTrials.gov — Search “thymosin alpha-1” for current and completed registered trials: clinicaltrials.gov
• SciClone Pharmaceuticals — Zadaxin prescribing information and approved country list: sciclone.com
• FDA Bulk Drug Substances List — Category 2 designation details: fda.gov
• WADA Prohibited List — Annual publication, current year: wada-ama.org
• Peptidings — TB-500 (Thymosin Beta-4 Fragment) Research Overview
• Peptidings — BPC-157 Research Overview
• Peptidings — GHK-Cu Research Overview
• Peptidings — Peptides Studied for Inflammation and Autoimmune Conditions
• Peptidings — Peptide Research Glossary — definitions for TLR signaling, Th1/Th2 polarization, seroconversion, sepsis, and other terms used in this article